Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gyre Therapeutics ( (GYRE) ) has shared an announcement.
On May 4, 2026, Gyre Therapeutics completed its previously announced all-stock, approximately $300 million acquisition of Cullgen Inc., a clinical-stage developer of targeted protein degraders and degrader-antibody conjugates, with Cullgen becoming a wholly owned subsidiary. The deal creates a fully integrated biopharmaceutical group spanning the U.S. and China, combining Gyre’s commercial ETUARY franchise and late-stage fibrosis assets with Cullgen’s targeted protein degradation platform, and maintains the combined company’s Nasdaq listing under the ticker GYRE.
As part of the transaction, former Cullgen chief executive Ying Luo was appointed President and Chief Executive Officer of Gyre and joined its board, while Ping Zhang remains Chairman, and Thomas Eastling moved into the Chief Financial Officer role. Gyre also assumed Cullgen’s stock incentive plan and established a new class of preferred stock with specific voting and conversion features, a capital structure change that could influence future dilution and governance dynamics for shareholders while supporting the company’s expanded pipeline and cross-border growth ambitions.
The most recent analyst rating on (GYRE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.
Spark’s Take on GYRE Stock
According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.
The score is primarily supported by improving profitability and a low-leverage balance sheet, plus positive regulatory/M&A milestones. It is held back by weak and volatile cash generation, bearish technicals (below major moving averages with negative MACD), and a very high P/E valuation.
To see Spark’s full report on GYRE stock, click here.
More about Gyre Therapeutics
Gyre Therapeutics, Inc. is a San Diego-based, commercial-stage biopharmaceutical company focused on developing and commercializing therapies for organ fibrosis and inflammatory diseases. Through its majority-owned Chinese subsidiary Gyre Pharmaceuticals, the company markets ETUARY, the first approved treatment for idiopathic pulmonary fibrosis in China, and advances a pipeline led by the liver fibrosis drug candidate F351 and other fibrosis-focused programs.
Average Trading Volume: 93,432
Technical Sentiment Signal: Sell
Current Market Cap: $756.6M
For detailed information about GYRE stock, go to TipRanks’ Stock Analysis page.